about
Prevalence and pathogenesis of hypokalemia in patients on chronic peritoneal dialysis: one center's experience and review of the literature.Potassium metabolism in patients with chronic kidney disease. Part II: patients on dialysis (stage 5).Acute renal failure in the elderly: particular characteristics.Total hip arthroplasty for hip fractures: 5-year follow-up of functional outcomes in the oldest independent old and very old patients.Impaired Urine Dilution Capability in HIV Stable Patients.Dysfunction of the thick loop of Henle and senescence: from molecular biology to clinical geriatrics.Informatic nephrology.Hyperuricemia and chronic kidney disease: an enigma yet to be solved.Therapeutic alternatives and palliative care for advanced renal disease in the very elderly: a review of the literature.Impact of renal aging on drug therapy.Syndrome of rapid onset end stage renal disease in incident Mayo Clinic chronic hemodialysis patient.Frailty phenotype and chronic kidney disease: a review of the literature.Glomerular filtration rate equations: a comprehensive review.How to differentiate renal senescence from chronic kidney disease in clinical practice.Kidney-lung pathophysiological crosstalk: its characteristics and importance.Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity.Water, electrolyte, acid-base, and trace elements alterations in cirrhotic patients.Icodextrin and peritoneal dialysis: advantages and new applications.The Importance of Evaluating Frailty and Social-behavioral Factors for Managing Drugs and Dialysis Prescription in Elderly Patients.Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.Local ethanol injection for the treatment of deltoid parathyroid cell hyperplasia.Fractional excretion of K, Na and Cl following furosemide infusion in healthy, young and very old people.Renal physiology in elderly persons with severe immobility syndrome.Creatinine reabsorption by the aged kidney.Improvement in uremic symptoms after increasing daily dialysate volume in patients on chronic peritoneal dialysis with declining renal function.Ibandronate improves hyperphosphatemia in dialysis patients with hyperparathyroidism.Furosemide test in stage III-chronic kidney disease and kidney transplant patients on tacrolimus.Renal potassium excretion: comparison between chronic renal disease patients and old people.Hyperphosphatemia and nicotinic acid in peritoneal dialysis patients.Novel acute kidney injury biomarkers: their characteristics, utility and concerns.Renal calcium, phosphorus, magnesium and uric acid handling: comparison between stage III chronic kidney disease patients and healthy oldest old.Art as a vital human function.Art as an instrument to understand the nature of suffering.Informatic nephrology: 17 years of one-center experience.The HUGE formula (hematocrit, urea, gender) for screening for chronic kidney disease in elderly patients: a study of diagnostic accuracy.Art as an educational tool in medicine.Tubular secretion in chronic kidney disease staging: a new proposal.Age and underdialysis as predictors of sleep disorders in peritoneal dialysis patients.Evaluation of HUGE equation (hematocrit, urea, gender) performance for screening chronic kidney disease in clinically stable cirrhotic patients.Are currently GFR estimating equations and standard Kt/V value adequate for advanced chronic kidney disease (CKD) frail elderly patients?
P50
Q35782288-1326E423-3F15-42F7-B3D1-1ECA50C87C71Q36077225-E7576F3A-5BC4-4FFE-BD35-13CDD9EEBC4CQ36679512-D7C382E0-989E-4C4D-A24F-3B477E0488AFQ37654741-6E34833A-4155-4177-96BF-B37CCE6A7197Q37706095-5B17C849-F8B2-4EF6-9385-DD07839486AAQ37808968-71294FF0-1078-409D-BA4B-54DB69882E53Q38052085-678CD083-4611-4456-AB0B-8F95E2DE8045Q38238942-7648FE57-DEFB-4A3A-A56A-6D39FE289315Q38283142-1097E748-CF6A-4915-8E28-C1BA12F4B7CEQ38544072-691B187C-11BC-40BD-8D39-352321B9B009Q38545793-DDD98D8A-F15D-4469-A990-0937233780E1Q38593980-98943939-7848-47A3-8EE2-0BCA074A780AQ38800026-ECC52DCC-F79C-4BA8-9DF1-AA719A4B1B50Q38887707-802B8478-0017-4171-85B2-89B735F2A5A5Q39236828-18E20E91-4FF0-47CE-85B2-95FE579764C9Q39251479-1993A943-E6C8-458E-AF08-39E465F91B4CQ39368656-DBBF8357-C620-4F54-869C-0D54D3C36C6CQ39413030-4FAFD791-5380-4914-BC2C-E35DEF27A3F9Q41119645-B4D3228E-3304-4C01-BF14-A92367960E24Q42933107-4869E96C-43C1-4AD8-9E6E-E04352430BD6Q45763199-2472ED1D-98A4-45C3-8D19-B4AF4DF0FF3AQ46092372-52EC93D2-A8F8-4F66-9230-842935A00B52Q46092373-34B424C4-F146-4FEC-BB78-B60513D7EB15Q46179898-CC4D7E27-2D6A-4F2D-AA03-F096D4E76139Q46397130-9366C0C4-AD31-499C-870E-6602994F7B27Q46400619-96D00462-7F3E-46E3-A607-31F9DA5DFDEAQ46421487-8241DD8A-2E5D-47C5-9221-8DAF7C8843D5Q46678684-EF313E87-0634-4694-BDBC-EBD5967BC574Q46816731-E0CFBA11-39F3-4146-ADDC-90EA68859245Q47226942-99E377B2-8CF6-4B24-B5EE-5DF42BCF7D4EQ47262717-8CA52CA6-0ADB-41E1-95BF-3031F2AF5708Q47701294-983A5F84-06F6-473C-8079-94847A0150F2Q47753132-1FCF4CF2-B314-49E1-A4D0-549C7C8A35F0Q48005128-05E07507-42EF-45FF-AB73-3AE77F8D8644Q48026794-FCF519AB-D33C-49CF-A176-A5791A8ECD61Q48060987-13936C8C-D732-4F48-8DF6-41930CAE6FCCQ48293126-8D55B064-C2D0-45E1-88D5-21A8FA23461FQ48494493-EBCF0D09-5822-4D04-A558-101E7C8A1EC3Q50631683-0EEAAB36-DA85-43A2-B355-1CAD0B164482Q50911017-8187C4F8-B927-4912-8815-634E2E98F82B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carlos G Musso
@es
Carlos G Musso
@nl
Carlos G Musso
@sl
Carlos G. Musso
@en
type
label
Carlos G Musso
@es
Carlos G Musso
@nl
Carlos G Musso
@sl
Carlos G. Musso
@en
prefLabel
Carlos G Musso
@es
Carlos G Musso
@nl
Carlos G Musso
@sl
Carlos G. Musso
@en
P1153
P106
P1153
23968939500
56405307400
7003468350
P21
P31
P496
0000-0001-8666-1130